ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bayer, Regeneron Link For Eye Disease

October 23, 2006 | APPEARED IN VOLUME 84, ISSUE 43

Bayer HealthCare and Regeneron Pharmaceuticals will collaborate to develop Regeneron's VEGF Trap-Eye for the treatment of eye disease. VEGF Trap-Eye is a protein that binds to or "traps" vascular endothelial growth factor, thought to play a critical role in eye disease. The drug is currently in Phase I and II clinical trials. Regeneron will get $75 million up front from Bayer and will be eligible for milestone payments of up to $245 million. The firms will jointly commercialize VEGF Trap-Eye outside the U.S.; Regeneron has all U.S. rights.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment